Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis

Abstract Background This study aimed to determine the influence of tocilizumab (TCZ) in modifying the clinical and laboratory features of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (s-JIA). Furthermore, we assessed the performance of the 2016 MAS classif...

Full description

Bibliographic Details
Main Authors: Masaki Shimizu, Mao Mizuta, Nami Okamoto, Takahiro Yasumi, Naomi Iwata, Hiroaki Umebayashi, Yuka Okura, Noriko Kinjo, Tomohiro Kubota, Yasuo Nakagishi, Kenichi Nishimura, Mariko Mohri, Masato Yashiro, Junko Yasumura, Hiroyuki Wakiguchi, Masaaki Mori
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Pediatric Rheumatology Online Journal
Subjects:
Macrophage activation syndrome
Systemic juvenile idiopathic arthritis
Tocilizumab
Classification criteria
Online Access:https://doi.org/10.1186/s12969-020-0399-1

Internet

https://doi.org/10.1186/s12969-020-0399-1

Similar Items